Imaging Early Changes in Proliferation at 1 Week Post Chemotherapy: a Pilot Study in Breast Cancer Patients with 3'-deoxy-3'-[18F]fluorothymidine Positron Emission Tomography

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2007 Mar 3

PMID 17333178

Citations 110

Authors

Laura Kenny

R Charles Coombes

David M Vigushin

Adil Al-Nahhas

Sami Shousha

Eric O Aboagye

Affiliations

Soon will be listed here.

Abstract

Purpose: 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography ([18F]FLT-PET) has been developed for imaging cell proliferation and findings correlate strongly with the Ki-67 labelling index in breast cancer. The aims of this pilot study were to define objective criteria for [18F]FLT response and to examine whether [18F]FLT-PET can be used to quantify early response of breast cancer to chemotherapy.

Methods: Seventeen discrete lesions in 13 patients with stage II-IV breast cancer were scanned prior to and at 1 week after treatment with combination 5-fluorouracil, epirubicin and cyclophosphamide (FEC) chemotherapy. The uptake at 90 min (SUV90) and irreversible trapping (Ki) of [18F]FLT were calculated for each tumour. The reproducibility of [18F]FLT-PET was determined in nine discrete lesions from eight patients who were scanned twice before chemotherapy. Clinical response was assessed at 60 days after commencing FEC.

Results: All tumours showed [18F]FLT uptake and this was reproducible in serial measurements (SD of mean % difference=10.5% and 15.1%, for SUV90 and Ki, respectively; test-retest correlation coefficient>or=0.97). Six patients had a significant clinical response (complete or partial) at day 60; these patients also had a significant reduction in [18F]FLT uptake at 1 week. Decreases in Ki and SUV90 at 1 week discriminated between clinical response and stable disease (p=0.022 for both parameters). In three patients with multiple lesions there was a mixed [18F]FLT response in primary tumours and metastases. [18F]FLT response generally preceded tumour size changes.

Conclusion: [18F]FLT-PET can detect changes in breast cancer proliferation at 1 week after FEC chemotherapy.

Citing Articles

A PET probe targeting polyamine transport system for precise tumor diagnosis and therapy.

Zhou M, Yin X, Chen B, Hu S, Zhou W Asian J Pharm Sci. 2024; 19(3):100924.

PMID: 38903130 PMC: 11186966. DOI: 10.1016/j.ajps.2024.100924.

Repeatability of F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials.

Muzi M, Peterson L, Specht J, Hippe D, Novakova-Jiresova A, Lee J EJNMMI Res. 2024; 14(1):32.

PMID: 38536511 PMC: 10973316. DOI: 10.1186/s13550-024-01093-7.

A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show F-Fluorothymidine "Flare" on Positron Emission Tomography.

Aravind P, Popat S, Barwick T, Soneji N, Lythgoe M, Sreter K Cancers (Basel). 2023; 15(14).

PMID: 37509378 PMC: 10377924. DOI: 10.3390/cancers15143718.

Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).

Sunassee E, Jardim-Perassi B, Madonna M, Ordway B, Ramanujam N Mol Cancer Res. 2023; 21(10):995-1009.

PMID: 37343066 PMC: 10592445. DOI: 10.1158/1541-7786.MCR-22-1004.

Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology.

Mankoff D, Pantel A, Viswanath V, Karp J Curr Pathobiol Rep. 2023; 7(3):97-108.

PMID: 37092138 PMC: 10117535. DOI: 10.1007/s40139-019-00202-9.

References

Wells P, Gunn R, Steel C, Ranicar A, Brady F, Osman S . 2-[11C]thymidine positron emission tomography reproducibility in humans. Clin Cancer Res. 2005; 11(12):4341-7. DOI: 10.1158/1078-0432.CCR-04-1818. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Dowsett M, Archer C, Assersohn L, Gregory R, Ellis P, Salter J . Clinical studies of apoptosis and proliferation in breast cancer. Endocr Relat Cancer. 2000; 6(1):25-8. DOI: 10.1677/erc.0.0060025. View

Weber W, Ziegler S, Thodtmann R, Hanauske A, Schwaiger M . Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999; 40(11):1771-7. View

Wahl R, Zasadny K, Helvie M, Hutchins G, Weber B, Cody R . Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993; 11(11):2101-11. DOI: 10.1200/JCO.1993.11.11.2101. View

Pio B, Park C, Pietras R, Hsueh W, Satyamurthy N, Pegram M . Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2005; 8(1):36-42. DOI: 10.1007/s11307-005-0029-9. View

Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G . [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?. Eur J Nucl Med Mol Imaging. 2003; 30(5):682-8. DOI: 10.1007/s00259-003-1120-6. View

van Waarde A, Cobben D, Suurmeijer A, Maas B, Vaalburg W, de Vries E . Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004; 45(4):695-700. View

Buck A, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G . Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003; 44(9):1426-31. View

10.

Ellis M, Rosen E, Dressman H, Marks J . Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. J Steroid Biochem Mol Biol. 2003; 86(3-5):301-7. DOI: 10.1016/s0960-0760(03)00371-6. View

11.

Minn H, Zasadny K, Quint L, Wahl R . Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology. 1995; 196(1):167-73. DOI: 10.1148/radiology.196.1.7784562. View

12.

Vincent-Salomon A, Rousseau A, Jouve M, Beuzeboc P, Sigal-Zafrani B, Freneaux P . Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer. 2004; 40(10):1502-8. DOI: 10.1016/j.ejca.2004.03.014. View

13.

Dehdashti F, Flanagan F, Mortimer J, Katzenellenbogen J, Welch M, Siegel B . Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999; 26(1):51-6. DOI: 10.1007/s002590050359. View

14.

Archer C, Parton M, Smith I, Ellis P, Salter J, Ashley S . Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer. 2003; 89(6):1035-41. PMC: 2376965. DOI: 10.1038/sj.bjc.6601173. View

15.

Shields A, Grierson J, Muzik O, Stayanoff J, Lawhorn-Crews J, Obradovich J . Kinetics of 3'-deoxy-3'-[F-18]fluorothymidine uptake and retention in dogs. Mol Imaging Biol. 2003; 4(1):83-9. DOI: 10.1016/s1095-0397(01)00070-x. View

16.

van Diest P, van der Wall E, Baak J . Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004; 57(7):675-81. PMC: 1770351. DOI: 10.1136/jcp.2003.010777. View

17.

Kenny L, Vigushin D, Al-Nahhas A, Osman S, Luthra S, Shousha S . Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 2005; 65(21):10104-12. DOI: 10.1158/0008-5472.CAN-04-4297. View

18.

Korn E, Arbuck S, Pluda J, Simon R, Kaplan R, Christian M . Clinical trial designs for cytostatic agents: are new approaches needed?. J Clin Oncol. 2001; 19(1):265-72. DOI: 10.1200/JCO.2001.19.1.265. View

19.

Ellis M, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F . Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003; 63(19):6523-31. View

20.

Singletary S, Allred C, Ashley P, Bassett L, Berry D, Bland K . Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002; 20(17):3628-36. DOI: 10.1200/JCO.2002.02.026. View